

The **CONNECT** Clinical Trial

The first ever multi-center, randomized, controlled trial using Dexcom Continuous Glucose Monitoring (CGM) Systems as the intervention for type 2 non-insulin taking patients.

STUDY PURPOSE

To demonstrate the benefit of Dexcom CGM for glucose control in type 2 non-insulin taking populations.

STUDY OVERVIEW



283 randomized patients with type 2 diabetes not using insulin:

- Dexcom CGM (n=145)
- Control Group (n=138)



26 weeks



Over **22 primary care practices** throughout the US

- + All patients were provided diabetes education on diet and exercise
- + Continued pre-study glucose-lowering medications (40% of patients were on a GLP-1)
- + All patients were given a blood glucose meter (BGM)


THE LARGEST A1C REDUCTION IN THE TYPE 2 NON-INSULIN TAKING POPULATION*

*Based on randomized control trials

OVERALL RESULTS


BASELINE MEAN A1C = 8.8%

1.6% A1C DECREASE USING DEXCOM CGM



RESULTS WITH BASELINE A1C ≥ 10%

3.1% A1C DECREASE USING DEXCOM CGM



Over 2/3 of Dexcom CGM patients reached **less than 7.5% A1C**.



Nearly **half** reached **less than 7.0% A1C**.



Improvement in A1C is associated with reduce risk of long term diabetes-related complications.¹



Consistent improvement in A1C observed with Dexcom CGM across all ages, gender, education level, BMI, insurance, income and across racial and ethnic groups.


SIGNIFICANTLY HIGHER A1C REDUCTION WITH DEXCOM & GLP-1 THAN WITH GLP-1 ALONE:



OVERALL, A SIGNIFICANT TIME IN RANGE (TIR) IMPROVEMENT AS EARLY AS WEEK 1 AND SUSTAINED OVERTIME

CLINICAL AND STATISTICALLY SIGNIFICANT INCREASE IN TIR

On average, TIR doubled for patients using Dexcom:



5 hour TIR increase on average with Dexcom CGM.



21% TIR increase between group difference.

More TIR means fewer highs and more stable glucose—helping people with type 2 diabetes not using insulin stay in control and reduce risk over time.^{1,2}

Martens, T. Presented at American Diabetes Association 2026 Scientific Sessions, June 6, 2026; New Orleans, LA; USA. 1 Reed J, et al. *Diabetes Obes Metab.* 2024;26(7):2881-9. 2 Layne JE, et al. *Diabetes Technol Ther.* 2024;26(12):925-31. Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. ©2026 Dexcom, Inc. All rights reserved. MAT-14983

OVER 2X MORE PATIENT ENGAGEMENT WITH DEXCOM CGM VS SMBG



97%

median daily Dexcom CGM usage throughout the 26 weeks vs 41% daily SMBG use in the control group

Patients using Dexcom CGM reported the following compared to SMBG:

- ✓ Greater satisfaction
- ✓ Reduced diabetes-related distress
- ✓ Reduced impact on diabetes quality of life



Dexcom